Regulated CBD & cannabis industry: Dunbar Pharma will showcase its EU GMP-certified, plant-derived dronabinol API at expopharm 2026 in Munich, pitching “quality beyond the certificate” and long-term supply continuity for pharmacists. Clinical CBD research: Avecho’s pivotal cannabidiol insomnia trial cleared a key interim review, with an independent monitoring board recommending the study continue at its planned size, while recruitment for the final stage restarts. Company moves in medicinal cannabis: Little Green Pharma completed its Cannatrek merger, expanding cultivation/manufacturing and clinic operations across Australia and Europe, and the market is watching integration and cost synergies. Policy & risk around hemp THC: Texas coverage highlights tighter restrictions on hemp-derived THC products after a Texas Supreme Court ruling, with critics pointing to confusing rules and harsh penalties. Insurance/coverage implications: A separate analysis argues a federal ban on intoxicating hemp products will reshape risk and coverage, citing a new “total THC” approach and low per-container limits that could make most current products federally unlawful. Enforcement pressure: Phuket dispensaries faced permit losses and suspensions after an enforcement drive, with alleged breaches spanning traditional medicine and food regulations. Workforce & safety training: Oklahoma’s cannabis industry is pushing workforce training after a fatal THC extraction facility explosion, with colleges partnering on online safety and compliance courses.